Illumina Reports Preliminary Q4 Revenue Growth, Flat Full-Year 2025 Results
ILMN has more than doubled off its 52-week low of $68.7.
Summary
Illumina announced preliminary unaudited financial results for Q4 and fiscal year 2025, showing modest revenue growth in the quarter but flat revenue for the full year.
Key Events · Earnings and Guidance · ILMN
-
Preliminary Q4 2025 Revenue Growth
Illumina reported preliminary Q4 2025 revenue of approximately $1.155 billion, representing a 5% increase (4% constant currency) from Q4 2024.
-
Flat Full-Year 2025 Revenue
Preliminary fiscal year 2025 revenue was approximately $4.34 billion, remaining flat compared to fiscal year 2024.
-
Ex-China Revenue Performance
Ex-China revenue showed stronger growth, up 7% in Q4 2025 and 2% for the full fiscal year 2025.
-
Preliminary EPS Figures
Preliminary GAAP diluted EPS for Q4 2025 ranged from $2.14 to $2.17, with non-GAAP diluted EPS from $1.27 to $1.30.
Analysis · ILMN · Industrial Applications And Services
Illumina's preliminary financial results provide an early look at its performance, with Q4 2025 revenue showing a 5% increase, driven by ex-China growth. However, the full fiscal year 2025 revenue remained flat compared to the prior year, which could be a point of concern for investors in a growth-oriented company. The release of these preliminary figures ahead of the J.P. Morgan Healthcare Conference aims to set expectations, but the final audited results on February 5, 2026, will be crucial for a complete assessment.
At the time of this filing, ILMN was trading at $146.64 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $22.5B. The 52-week trading range was $68.70 to $153.06. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.